These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 38242720)

  • 1. Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial.
    Andresen NK; Røssevold AH; Quaghebeur C; Gilje B; Boge B; Gombos A; Falk RS; Mathiesen RR; Julsrud L; Garred Ø; Russnes HG; Lereim RR; Chauhan SK; Lingjærde OC; Dunn C; Naume B; Kyte JA
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38242720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer.
    Kyte JA; Andresen NK; Russnes HG; Fretland SØ; Falk RS; Lingjærde OC; Naume B
    J Transl Med; 2020 Jul; 18(1):269. PubMed ID: 32620163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.
    Motzer RJ; Escudier B; McDermott DF; Arén Frontera O; Melichar B; Powles T; Donskov F; Plimack ER; Barthélémy P; Hammers HJ; George S; Grünwald V; Porta C; Neiman V; Ravaud A; Choueiri TK; Rini BI; Salman P; Kollmannsberger CK; Tykodi SS; Grimm MO; Gurney H; Leibowitz-Amit R; Geertsen PF; Amin A; Tomita Y; McHenry MB; Saggi SS; Tannir NM
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32661118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50).
    Kato K; Doki Y; Ogata T; Motoyama S; Kawakami H; Ueno M; Kojima T; Shirakawa Y; Okada M; Ishihara R; Kubota Y; Amaya-Chanaga C; Chen T; Matsumura Y; Kitagawa Y
    Esophagus; 2023 Apr; 20(2):291-301. PubMed ID: 36401133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma.
    Rini BI; Signoretti S; Choueiri TK; McDermott DF; Motzer RJ; George S; Powles T; Donskov F; Tykodi SS; Pal SK; Gupta S; Lee CW; Jiang R; Tannir NM
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36549781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG.
    Glutsch V; Schummer P; Kneitz H; Gesierich A; Goebeler M; Klein D; Posch C; Gebhardt C; Haferkamp S; Zimmer L; Becker JC; Leiter U; Weichenthal M; Schadendorf D; Ugurel S; Schilling B
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.
    Tomita Y; Kondo T; Kimura G; Inoue T; Wakumoto Y; Yao M; Sugiyama T; Oya M; Fujii Y; Obara W; Motzer RJ; Uemura H
    Jpn J Clin Oncol; 2020 Jan; 50(1):12-19. PubMed ID: 31633185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of first-line immunotherapies for advanced non-small cell lung cancer.
    Yang SC; Ou HT; Su WC; Wang SY
    Cancer Med; 2023 Apr; 12(7):8838-8850. PubMed ID: 36653947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.
    Albiges L; Tannir NM; Burotto M; McDermott D; Plimack ER; Barthélémy P; Porta C; Powles T; Donskov F; George S; Kollmannsberger CK; Gurney H; Grimm MO; Tomita Y; Castellano D; Rini BI; Choueiri TK; Saggi SS; McHenry MB; Motzer RJ
    ESMO Open; 2020 Nov; 5(6):e001079. PubMed ID: 33246931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the efficacy and safety of nivolumab and ipilimumab combination therapy compared to nivolumab monotherapy in advanced cancers (excluding melanoma): a systemic review and meta-analysis.
    Rangwala HS; Fatima H; Ali M; Sunder S; Devi S; Rangwala BS; Abbas SR
    J Egypt Natl Canc Inst; 2024 May; 36(1):14. PubMed ID: 38705953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908.
    Dunkel IJ; Doz F; Foreman NK; Hargrave D; Lassaletta A; André N; Hansford JR; Hassall T; Eyrich M; Gururangan S; Bartels U; Gajjar A; Howell L; Warad D; Pacius M; Tam R; Wang Y; Zhu L; Cohen K
    Neuro Oncol; 2023 Aug; 25(8):1530-1545. PubMed ID: 36808285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis.
    O'Byrne K; Popoff E; Badin F; Lee A; Yuan Y; Lozano-Ortega G; Eccles LJ; Varol N; Waser N; Penrod JR; Goring S
    Lung Cancer; 2023 Mar; 177():11-20. PubMed ID: 36669321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial.
    George DJ; Spigel DR; Gordan LN; Kochuparambil ST; Molina AM; Yorio J; Rezazadeh Kalebasty A; McKean H; Tchekmedyian N; Tykodi SS; Zhang J; Askelson M; Johansen JL; Hutson TE
    BMJ Open; 2022 Sep; 12(9):e058396. PubMed ID: 36104138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.
    Motzer RJ; McDermott DF; Escudier B; Burotto M; Choueiri TK; Hammers HJ; Barthélémy P; Plimack ER; Porta C; George S; Powles T; Donskov F; Gurney H; Kollmannsberger CK; Grimm MO; Barrios C; Tomita Y; Castellano D; Grünwald V; Rini BI; McHenry MB; Lee CW; McCarthy J; Ejzykowicz F; Tannir NM
    Cancer; 2022 Jun; 128(11):2085-2097. PubMed ID: 35383908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial.
    Røssevold AH; Andresen NK; Bjerre CA; Gilje B; Jakobsen EH; Raj SX; Falk RS; Russnes HG; Jahr T; Mathiesen RR; Lømo J; Garred Ø; Chauhan SK; Lereim RR; Dunn C; Naume B; Kyte JA
    Nat Med; 2022 Dec; 28(12):2573-2583. PubMed ID: 36482103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma
    Tarhini AA; Toor K; Chan K; McDermott DF; Mohr P; Larkin J; Hodi FS; Lee CH; Rizzo JI; Johnson H; Moshyk A; Rao S; Kotapati S; Atkins MB
    ESMO Open; 2021 Apr; 6(2):100050. PubMed ID: 33556898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer.
    Perez BA; Kim S; Wang M; Karimi AM; Powell C; Li J; Dilling TJ; Chiappori A; Latifi K; Rose T; Lannon A; MacMillan G; Saller J; Grass GD; Rosenberg S; Gray J; Haura E; Creelan B; Tanvetyanon T; Saltos A; Shafique M; Boyle TA; Schell MJ; Conejo-Garcia JR; Antonia SJ
    Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):425-435. PubMed ID: 33002543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab.
    Chapman PB; Jayaprakasam VS; Panageas KS; Callahan M; Postow MA; Shoushtari AN; Wolchok JD; Betof Warner A
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34702752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial.
    Albiges L; Tannir NM; Burotto M; McDermott D; Plimack ER; Barthélémy P; Porta C; Powles T; Donskov F; George S; Kollmannsberger CK; Gurney H; Grimm MO; Tomita Y; Castellano D; Rini BI; Choueiri TK; Leung D; Saggi SS; Lee CW; McHenry MB; Motzer RJ
    Eur Urol; 2022 Mar; 81(3):266-271. PubMed ID: 34750035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402).
    Piulats JM; Espinosa E; de la Cruz Merino L; Varela M; Alonso Carrión L; Martín-Algarra S; López Castro R; Curiel T; Rodríguez-Abreu D; Redrado M; Gomà M; Rullán AJ; Calvo González A; Berrocal-Jaime A
    J Clin Oncol; 2021 Feb; 39(6):586-598. PubMed ID: 33417511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.